Slingshot members are tracking this event:
Topline results released for Novartis' (NVS) Phase III study of ACZ885 (canakinumab) in reducing cardiovascular risk in people who survived a heart attack
Slingshot Insights Explained
Jun 22, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Acz885, Canakinumab, Heart Attack, Cardiovascular Risk